StockData
Nuvation Bio Inc. logo

Nuvation Bio Inc. (NUVB) stock

NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30107% above fair value
$3.78−0.12 (-3.08%)

Close on Nov 18, 2026Market cap $1.33BP/E –Yield –

Nuvation Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Nuvation Bio's operating income for the twelve months ending Jun 30, 2026 was -$137.63M. For fiscal 2025 it was -$213.06M. The highest annual figure on record is -$43.55M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$213.06M–
FY2024Dec 31, 2024-$592.63M–
FY2023Dec 31, 2023-$99.82M–
FY2022Dec 31, 2022-$119.73M–
FY2021Dec 31, 2021-$93.32M–
FY2020Dec 31, 2020-$43.55M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$51.04M–
Q1 FY2026Mar 31, 2026$3.88M–
Q4 FY2025Dec 31, 2025-$34.04M–
Q3 FY2025Sep 30, 2025-$56.43M–
Q2 FY2025Jun 30, 2025-$63.59M–
Q1 FY2025Mar 31, 2025-$59.00M–
Q4 FY2024Dec 31, 2024-$53.94M–
Q3 FY2024Sep 30, 2024-$48.10M–
Q2 FY2024Jun 30, 2024-$470.39M–
Q1 FY2024Mar 31, 2024-$20.20M–
Q4 FY2023Dec 31, 2023-$20.83M–
Q3 FY2023Sep 30, 2023-$26.34M–
Q2 FY2023Jun 30, 2023-$26.13M–
Q1 FY2023Mar 31, 2023-$26.52M–
Q4 FY2022Dec 31, 2022-$24.34M–
Q3 FY2022Sep 30, 2022-$29.34M–
Q2 FY2022Jun 30, 2022-$37.87M–
Q1 FY2022Mar 31, 2022-$28.19M–
Q4 FY2021Dec 31, 2021-$29.61M–
Q3 FY2021Sep 30, 2021-$22.79M–
Q2 FY2021Jun 30, 2021-$20.43M–
Q1 FY2021Mar 31, 2021-$20.48M–
Q4 FY2020Dec 31, 2020-$13.77M–
Q3 FY2020Sep 30, 2020-$11.55M–
Q2 FY2020Jun 30, 2020-$9.02M–
Q1 FY2020Mar 31, 2020-$9.22M–

More Nuvation Bio figures

See a number that looks wrong?